Literature DB >> 30159356

Erythema Sweetobullosum: A Reactive Cutaneous Manifestation of Coccidioidomycosis.

Hisham Abukamleh1, Arash Heidari1, Greti Petersen1, Piruthiviraj Natarajan1, Gian Yakoub1, Everardo Cobos1, Royce Johnson1.   

Abstract

Reactive cutaneous coccidioidal skin manifestations are commonly noticed during the early stage of coccidioidomycosis. These skin lesions are devoid of any active coccidioidal organism, and the immune trigger mechanisms are not elucidated. We describe 6 cases of unusual reactive cutaneous coccidioidal manifestation, characterized by painful vesiculobullous lesions known as erythema sweetobullosum. The biopsy of the lesions revealed neutrophilic dermatosis with inflammatory cells resulting in a cleft and elevation of the most superficial layer of the skin forming a bulla. The reactive cutaneous lesion is self-limited and requires no specific therapy.

Entities:  

Keywords:  coccidioidomycosis; cutaneous manifestation; erythema sweetobullosum; noninfectious

Year:  2018        PMID: 30159356      PMCID: PMC6109837          DOI: 10.1177/2324709618796659

Source DB:  PubMed          Journal:  J Investig Med High Impact Case Rep        ISSN: 2324-7096


Background

Immune-mediated skin reactions to coccidioidomycosis manifest commonly as erythema nodosum and erythema multiforme.[1] A less well known noninfectious cutaneous manifestation of coccidioidomycosis is termed erythema sweetobullosum (ESB). This manifests as vesiculobullous eruptions predominantly found in upper arms and contiguous chest and was named erythema sweetobullosum by dermatologist Dr David J. Elbaum in 1998.[2] Coccidioidomycosis is caused by Coccidioides immitis and posadasii, which result in an identical spectrum of illness. The disease is endemic to Southwestern United states, Northwestern Mexico, Central America, Brazil, and Argentina. There is a new endemic cluster in eastern Washington state.[3] Annually, 150 000 infections are estimated to occur in the United States.[3,4] Approximately 60% of the infected are asymptomatic. Roughly 40% of the infected are symptomatic, and only 10% of them are diagnosed.[4,5] The primary pulmonary infection typically presents as community-acquired pneumonia. About 1% of the infected develop disseminated disease, pathologically exhibiting granulomatous lesions with endosporulating spherules. Reactive cutaneous manifestations can be seen in up to 50% of the primary pulmonary infections.[1,6,7]

Case Presentation

Case 1

A 40-year-old female presented at the emergency department with painful rash associated with intermittent fever and joint pain for 5 days (Figure 1). The rash was recognized initially over the neck and bilateral upper extremities, which subsequently spread to the legs. Multiple tense raised vesicles and bullous lesions were noticed bilaterally over the forearm and arm with several lesions associated with drainage and others crusted. Some of the bullous lesions had surrounding erythema. Laboratory examination revealed a white blood cell (WBC) count of 15.5 × 103/µL with an absolute eosinophil count (AEC) of 1600 cells/µL. The coccidioidal serology was positive by immunodiffusion for immunoglobulin M antibody (ID-IgM). The complement fixation (CF) antibody titer was <1:2. Chest X-ray revealed right upper lobe infiltrate. She received fluconazole 800 mg daily, and subsequent follow-up showed a nonreactive ID-IgM but weakly reactive ID-IgG and CF titer of 1:2. The punch biopsy of the drained bullous lesions of the right leg (Figure 1) showed superficial dermal edema enriched with lymphohistiocytic inflammation (Figure 2). The periodic acidSchiff stain and Gomori methenamine silver nitrate stain were negative for fungal organisms.
Figure 1.

Drained bullous lesions on the right leg.

Figure 2.

H&E at 10X magnification.

DE, dermal edema; LHC, lymphohistiocytic inflammatory cells.

Drained bullous lesions on the right leg. H&E at 10X magnification. DE, dermal edema; LHC, lymphohistiocytic inflammatory cells.

Case 2

A 45-year-old female presented with skin rash for 8 days (Figure 3). Rash was initially noticed on the right arm, which spread to the left arm and trunk. The patient complained of nonproductive cough, arthralgia, and weight loss. On examination, vesiculobullous, pruritic rashes with tenderness around the lesions were noticed. Biopsy of the forearm bullae lesion revealed histiocytes and neutrophils in the subepidermal layers with break in the epithelial lining. She received fluconazole 400 mg. Laboratory examination revealed a WBC count of 12.1 × 103/µL with an AEC of 1100 cells/µL. The coccidioidal serology showed weakly reactive ID-IgM and ID-IgG. CF antibody titer was 1:2. One month later she returned to the clinic with complete resolution of the rash.
Figure 3.

Bullous lesions on the forearm with raised plaques.

Bullous lesions on the forearm with raised plaques.

Case 3

A 47-year-old female presented with skin rash for 17 days (Figure 4). Initially the vesicular rash involved both forearms, which subsequently spread to the neck and both legs. The rash was notable for pruritic erythema around vesicular lesions. Biopsy of the lesions in the neck revealed granulomatous inflammation in the dermis (Figure 5). Laboratory tests revealed WBC count of 12.7 × 103/µL and AEC of 900 cells/µL. The coccidioidal serology was weakly reactive for ID-IgM and ID-IgG, and CF antibody titer was <1:2. Chest X-ray showed small right lower lobe infiltrate. The rash resolved in the next 2 weeks.
Figure 4.

Vesicles and bullous lesion on the arm.

Figure 5.

H&E at 20X magnification.

GIN, granulomatous inflammatory cells.

Vesicles and bullous lesion on the arm. H&E at 20X magnification. GIN, granulomatous inflammatory cells.

Case 4

A 42-year-old male presented with painful, pruritic vesiculobullous rash on his bilateral forearms for 15 days (Figure 6). The rash was red, raised, tense and vesiculobullous, and tender. He complained of fever and cough. Biopsy of the left forearm lesion revealed granulomatous inflammatory cells in the dermis with minimal subepidermal edema (Figure 7). The laboratory examination revealed WBC count of 12.3 × 103/µL and AEC of 800 cells/µL. The coccidioidal serology showed reactive ID-IgM and ID-IgG with CF antibody titer <1:2. The chest X-ray showed right lower lobe infiltrate. The skin biopsy showed subepidermal vesicular dermatitis with neutrophils and histiocytes. In the next 2 weeks, the rash resolved completely.
Figure 6.

Vesiculo-bullous lesion on the bilateral forearms.

Figure 7.

H&E at 20X magnification.

GIN, granulomatous inflammatory cells.

Vesiculo-bullous lesion on the bilateral forearms. H&E at 20X magnification. GIN, granulomatous inflammatory cells.

Case 5

A 45-year-old male presented with fever and diffuse maculopapular rash that started on bilateral forearms then over 4 days spread to lower extremities, shoulder, and posterior thorax (Figure 8). He complained of dry cough and mild pruritus over the chest. The laboratory examination showed WBC count of 16.7 × 103/µL with an AEC of 1600 cells/µL. Biopsy of the lesions in the posterior right arm revealed dermal edema and subepidermal vesicle with fibrin and irregular brown pigmentation in the epidermis (Figure 9). The coccidioidal serology showed weakly reactive ID-IgM and ID-IgG, and CF antibody titer was <1:2. Chest X-ray showed bilateral infiltrates worse on the left lower lobe. The rash resolved in the next 2 weeks.
Figure 8.

Vesiculo-bullous lesions on the arm.

Figure 9.

H&E at 20X magnification.

VS, vesiculated subepidermal layer.

Vesiculo-bullous lesions on the arm. H&E at 20X magnification. VS, vesiculated subepidermal layer.

Case 6

A 27-year-old Caucasian male presented with rash associated with myalgia and fever for 7 days (Figure 10). Multiple open and intact vesicles associated with erythematous subcutaneous tender nodules on both arms, legs, neck, and forehead were noted. There was clear, serous discharge from the vesicles. Biopsy of the crusted lesion over the left knee revealed vesiculated subepidermal layer with histiocytic inflammation of the dermis (Figure 11). Laboratory examination showed WBC count of 11.7 × 103/µL with an AEC of 1200 cells/µL. The chest X-ray showed right upper lobe inflammatory infiltration. The coccidioidal serology showed reactive ID-IgM and weakly reactive ID-IgG, and CF antibody titer was <1:2. The patient was discharged but lost to follow-up (see Table 1).
Figure 10.

Bilateral crusted bullous lesion the leg and knee.

Figure 11.

H&E at 20X magnification.

VL, vesiculated layer; SE, subepidermal edema.

Table 1.

Summary of Laboratory Reports.

CaseAge/SexDate of Presentation After Skin LesionLesion DistributionBiopsyWhite Blood CellsAbsolute Eosinophilic CountCF Titer
140/female5 DaysNeck, both arms subsequently to legsSuperficial dermal edema enriched with lymphohistiocytic inflammation15.5 × 103/µL1600 cells/µL<1:2
245/female8 DaysRight arm to left arm and trunkNeutrophils and histiocytes in the subepidermal layers with break in the epithelial lining12.1 × 103/µL1100 cells/µL1:2
347/female17 DaysBoth forearms spreading to legs and neckGranulomatous inflammation of the dermis12.7 × 103/µL900 cells/µL<1:2
442/male15 DaysBoth forearmsGranulomatous inflammation of the dermis with minimal subepidermal edema12.3 × 103/µL800 cells/µL<1:2
545/male4 DaysBilateral forearm, upper back, shoulder, and both legsSubepidermal vesicle with fibrin16.7 × 103/µL1600 cells/µL<1:2
627/male7 DaysBoth arms, legs, neck, and foreheadVesiculated subepidermal layer with histiocytic inflammation on the dermis11.7 × 103/µL1200 cells/µL<1:2

Abbreviation: CF, complement fixation.

Bilateral crusted bullous lesion the leg and knee. H&E at 20X magnification. VL, vesiculated layer; SE, subepidermal edema. Summary of Laboratory Reports. Abbreviation: CF, complement fixation. Laboratory results are summarized in Table 1.

Discussion

The skin manifestation of coccidioidal infection are broadly classified as reactive cutaneous and organism-specific manifestations.[1] The organism can be demonstrated at the site of the lesion with organism-specific manifestations whereas the reactive cutaneous manifestation is usually a delayed-type immune reaction.[1,8] The various reactive manifestations of Coccidioides are erythema nodosum, erythema multiforme, and ESB. Different type of cutaneous cell layer involvement results in different types of cutaneous manifestation. The exact immune triggers in each of these entities are largely unknown. A benign or asymptomatic coccidioidal infection results in a significant delayed-type immune response in the host associated with low or nondemonstrable complement fixing antibodies.[9] Conversely, a profound and multifocal infection is usually noted to have high CF antibodies and low delayed-type hypersensitivity.[10] All our patients had high absolute eosinophil levels. The reactive cutaneous manifestations occur very early in the disease and self-resolves within weeks. A biopsy of the bullous lesion usually shows dermatitis with epidermal layers infiltrated with eosinophil and phagocyte-rich stroma suggesting the inflammation lifting the most superficial layers of the skin producing the bullae. Similar histology was associated with vesicular lesions. The histologic features appear to change during the course, resulting in varied histologic findings within our cohort. Early biopsy showed features of lymphocyte-rich epidermal tissues with tissues edema and necrosis. It is followed by a distinct neutrophil predominant phase as it progresses. Macrophages with persistent tissue edema were noticed in older lesions. In the resolving phase, granulomatous features were noticed without demonstrable organism at these lesions. Even though the bullous lesions were extensive they regressed within few weeks, and there is no known role for corticosteroids to reduce the inflammation. The bullae can rupture and may require local care.

Conclusion

Erythema sweetobullosum is an inflammatory skin reaction presenting as clusters of painful, well-demarcated papules with central vesicular/bullae formation. It is more commonly found on arms but can be seen on lower extremities and trunk. It manifests in acute coccidioidomycosis infection and usually resolves in a short period without long-term sequelae. If there is a concern for the diagnosis, a skin biopsy may be of assistance.
  9 in total

Review 1.  Protective immunity in coccidioidomycosis.

Authors:  R A Cox; D M Magee
Journal:  Res Immunol       Date:  1998 May-Jun

Review 2.  Coccidioidomycosis: Recent Updates.

Authors:  Meryl Twarog; George R Thompson
Journal:  Semin Respir Crit Care Med       Date:  2015-09-23       Impact factor: 3.119

Review 3.  Coccidioidomycosis.

Authors:  D A Stevens
Journal:  N Engl J Med       Date:  1995-04-20       Impact factor: 91.245

Review 4.  State-of-the-art treatment of coccidioidomycosis: skin and soft-tissue infections.

Authors:  Janis E Blair
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 5.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Epidemiology of Acute Coccidioidomycosis with Erythema Nodosum ("San Joaquin" or "Valley Fever").

Authors:  C E Smith
Journal:  Am J Public Health Nations Health       Date:  1940-06

Review 7.  Virulence mechanisms of coccidioides.

Authors:  Chiung-Yu Hung; Jianmin Xue; Garry T Cole
Journal:  Ann N Y Acad Sci       Date:  2007-05-18       Impact factor: 5.691

Review 8.  Coccidioidomycosis and the skin: a comprehensive review.

Authors:  Sandra Cecilia Garcia Garcia; Julio Cesar Salas Alanis; Minerva Gomez Flores; Sergio Eduardo Gonzalez Gonzalez; Lucio Vera Cabrera; Jorge Ocampo Candiani
Journal:  An Bras Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.896

9.  Local Population Structure and Patterns of Western Hemisphere Dispersal for Coccidioides spp., the Fungal Cause of Valley Fever.

Authors:  David M Engelthaler; Chandler C Roe; Crystal M Hepp; Marcus Teixeira; Elizabeth M Driebe; James M Schupp; Lalitha Gade; Victor Waddell; Kenneth Komatsu; Eduardo Arathoon; Heidi Logemann; George R Thompson; Tom Chiller; Bridget Barker; Paul Keim; Anastasia P Litvintseva
Journal:  MBio       Date:  2016-04-26       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.